Log In
Print
BCIQ
Print
Print this Print this
 

Viaskin Peanut (DBV-712)

  Manage Alerts
Collapse Summary General Information
Company DBV Technologies S.A.
DescriptionPeanut proteins epicutaneously delivered by Viaskin patch technology
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationAllergy
Indication DetailsTreat peanut allergy; Treat peanut allergy in children ages 6-11
Regulatory Designation U.S. - Breakthrough Therapy (Treat peanut allergy in children ages 6-11);
U.S. - Fast Track (Treat peanut allergy)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today